RxDoctor Payments Data

Daljit Bagha, MD

Family Medicine · Houston, TXNPI 1225188162

Payments from drug & device makers

$1,611in general payments, 2019–2025

Across 85 payments — averaging $18.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Supernus Pharmaceuticals, Inc.$551
  • Lilly USA, LLC$196
  • Ironshore Pharmaceuticals Inc.$132
  • Novo Nordisk$112
  • Merck$79
  • Exact Sciences$70
  • plus $471 from 18 others

What the payments were for

  • Food & beverage$1,611100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,611 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$12,615
Medicare patients
70
Services billed
138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide17$23,808
JardianceEmpagliflozin13$15,749
FarxigaDapagliflozin Propanediol14$8,105
Rosuvastatin Calcium72$980
Atorvastatin Calcium86$677
Albuterol Sulfate HfaAlbuterol Sulfate23$660
Fluticasone Propionate42$616
Levothyroxine Sodium40$605
Montelukast Sodium30$384
Amlodipine Besylate52$327
Metoprolol Succinate18$313
Simvastatin18$300
Levocetirizine Dihydrochloride14$290
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav35$261
Metformin Hcl44$260

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$112$23,80817 claims
Boehringer IngelheimJardiance$57$15,74913 claims
AstraZenecaFarxiga$42$8,10514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →